{"content":"{\"Symbol\":[{\"ElementValue\":{\"@Type\":\"Alternate\",\"$\":\"FSP1\"},\"XRef\":{\"@Type\":\"MIM\",\"@ID\":\"182600\",\"@DB\":\"OMIM\"}},{\"ElementValue\":{\"@Type\":\"Preferred\",\"$\":\"SPG3A\"},\"XRef\":[{\"@Type\":\"MIM\",\"@ID\":\"182600\",\"@DB\":\"OMIM\"},{\"@ID\":\"5041\",\"@DB\":\"Office of Rare Diseases\"}]}],\"AttributeSet\":{\"Attribute\":{\"@Type\":\"public definition\",\"$\":\"Spastic paraplegia 3A (SPG3A) is a hereditary spastic paraplegia (HSP) characterized by progressive bilateral and mostly symmetric spasticity and weakness of the legs, diminished vibration sense caused by degeneration of the corticospinal tracts and dorsal columns, and urinary bladder hyperactivity. The average age of onset is four years. More than 80% of reported individuals manifest spastic gait before the end of the first decade of life. Most persons with early-onset SPG3A have a \\\"pure\\\" (\\\"uncomplicated\\\") HSP; however, complicated HSP with axonal motor neuropathy and/or distal amyotrophy with lower motor neuron involvement (Silver syndrome phenotype) have been observed. The rate of progression in SPG3A is slow, and wheelchair dependency or need for a walking aid (cane, walker, or wheelchair) is relatively rare.\"},\"XRef\":{\"@ID\":\"NBK45978\",\"@DB\":\"GeneReviews\"}},\"Citation\":{\"@Type\":\"review\",\"@Abbrev\":\"GeneReviews\",\"ID\":[{\"@Source\":\"PubMed\",\"$\":\"20862796\"},{\"@Source\":\"BookShelf\",\"$\":\"NBK45978\"}]}}","id":"15930","medgen_id":"C2931355","name":"Spastic paraplegia 3","alternate_names":["Spastic Paraplegia 3A","SPG3","FAMILIAL SPASTIC PARAPLEGIA, AUTOSOMAL DOMINANT, 1","SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT"],"type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"606439.0001\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0009\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"182600\",\"source_name\":\"FAMILIAL SPASTIC PARAPLEGIA, AUTOSOMAL DOMINANT, 1\"}","{\"db\":\"OMIM\",\"id\":\"606439.0008\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0002\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"182600\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5041\",\"source_name\":\"Spastic paraplegia 3\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK45978\",\"source_name\":\"Spastic Paraplegia 3A\"}","{\"db\":\"Orphanet\",\"id\":\"100984\",\"source_name\":null}","{\"db\":\"OMIM\",\"id\":\"606439.0005\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0013\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0007\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"182600\",\"source_name\":null}","{\"db\":\"Genetic Alliance\",\"id\":\"Spastic+paraplegia+3/6693\",\"source_name\":\"Spastic paraplegia 3\"}","{\"db\":\"OMIM\",\"id\":\"606439.0006\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0003\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"182600\",\"source_name\":\"SPG3\"}","{\"db\":\"OMIM\",\"id\":\"606439.0014\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0004\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}"]}
{"content":"{\"Citation\":[{\"@Type\":\"practice guideline\",\"@Abbrev\":\"Langer et al., 2012\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"22947299\"}},{\"@Type\":\"Recommendation\",\"@Abbrev\":\"SACHDNC, 2013\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23037933\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"EASAC/FEAM, 201\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23169492\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"NYMAC, 2014\",\"URL\":{\"$\":\"http://www.wadsworth.org/sites/default/files/WebDoc/68970143/DX_Guidelines_2014-10-01.pdf\"},\"CitationText\":{\"$\":\"Diagnostic Guidelines for Confirmation of Screen-Positive Newborn Screening Results\"}},{\"@Type\":\"Recommendation\",\"@Abbrev\":\"ACOG, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"25560141\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"ESHG/P3G/HUGO/PHGF, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"25626707\"}},{\"@Type\":\"general\",\"@Abbrev\":\"Alpha-1 Foundation, 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"24121147\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"NBSTRN, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"24394680\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"EUNENBS, 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23652378\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"NSGC, 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23881473\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"ACMG/ACOG/NSGC/PQF/SMFM, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"25730230\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"Skirton et al., 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"24022298\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"ACMG, 2013\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23619275\"}}]}","id":"32761","medgen_id":"C0950123","name":"Inborn genetic diseases","alternate_names":[],"type":"Disease","xrefs":["{\"db\":\"MeSH\",\"id\":\"D030342\",\"source_name\":null}"]}
